Cellectis

Cellectis Reports Financial Results for the Second Quarter 2026. To read the press release, click on the link in the first comment.

Cellectis to Report Second Quarter Financial Results on August 6, 2026. Full press release here: https://lnkd.in/evNBSjXB

Cellectis Reports Results from Shareholders Meeting Held on June 25, 2026. Read the full press release here: https://lnkd.in/evANJ93v

What did final Phase 1 data from BALLI-01 show for patients with relapsed/refractory B-ALL? At #EHA2026, Nitin Jain, M.D., Professor of Medicine, Department of Leukemia at UT MD Anderson, presented final Phase 1 results for lasme-cel in heavily pre-treated patients, many of whom had already failed CD19-directed CAR-T therapy. Among the Phase 2 target population (patients ≤50 years old treated at the recommended Phase 2 dose), the abstract reported a 100% overall response rate, with all patients proceeding to allogeneic stem cell transplant. In this AJMC - The American Journal of Managed Care interview, Dr. Jain discusses the manufacturing shift that improved response rates, how the recommended Phase 2 dose was selected, and the rationale behind the pivotal Phase 2 trial design. Watch the full interview below Link in the first comment 👇

This weekend, we were thrilled to have Nitin Jain, M.D., Professor of Medicine, Department of Leukemia at UT MD Anderson Cancer Center in Houston TX, presenting the final Phase 1 results for the BALLI-01 trial at #EHA2026.   Thank you, Nitin, Nicolas Boissel, and to the entire BALLI-01 investigator team for your commitment to patients with relapsed or refractory B-ALL.

Some patients with B-cell ALL have tried everything. Blinatumomab. Inotuzumab. CD19 CAR-T therapy. And still, the disease comes back.   For these patients, the question isn't which treatment to try next. It's whether they can get to one of the only thing that might cure them, an allogeneic stem cell transplant, before the disease makes it impossible.   Today at #EHA2026, we shared final Phase 1 results from BALLI-01, evaluating lasme-cel in patients with r/r B-ALL.   → 100% overall response rate in the target Phase 2 population (n=7) → All responding patients proceeded to transplant → A manageable safety profile   🎤 The data will be presented as an oral session on June 13 by Nitin Jain, M.D., Professor of Medicine, Department of Leukemia at the University of Texas MD Anderson Cancer Center in Houston, TX   To read the press release, see the link in the first comment. 

Cellectis Receives FDA RMAT Designation for Lasme-cel, the First Allogeneic CAR-T Therapy in a Pivotal Trial for Patients with r/r B-ALL.   The granting of RMAT designation reflects the FDA's recognition of the potential for lasme-cel to address the unmet medical need faced by patients with r/r B-ALL.   To read the press release, follow the link in the first comment.

It started with baking yeast. It changed the world.   In 1983, Professor Rodney Rothstein co-authored a paper with Jack Szostak, Terry Orr-Weaver, and Franklin Stahl that laid the foundation for modern gene editing: "The double-strand-break model for genetic recombination."   The discovery? How cells repair broken DNA, a mechanism uncovered in baker's yeast that would ultimately unlock the ability to precisely edit genomes across all living organisms.   Decades later, these principles underpin TALEN, the gene editing platform at the heart of Cellectis' allogeneic CAR T-cell therapies.   From that moment forward, everything changed.   We sat down with Rodney Rothstein, Professor of Genetics and Development at Columbia University, to hear the story behind the breakthrough that started it all. Enjoy the video! 👇

Cellectis’ Annual Shareholders General Meeting to be Held on June 25, 2026. Full press release here : https://lnkd.in/eesFyPkk